Drug Trial Radar · NCT06974812
IBI3014 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
Last checked: Nov 19, 2026Latest source record: Jan 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
250
Planned (sponsor's estimate)
Start
Apr 18, 2025
Primary completion
Jun 30, 2026
Study completion Jun 30, 2027
Sponsor
- Lead sponsor
- Innovent Biologics (Suzhou) Co. Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 16, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 1/2 multicenter, multi-regional, open-label, first-in-human study of IBI3014 in participants with unresectable locally advanced or metastatic solid tumors.
Conditions
- Unresectable Locally Advanced or Metastatic Solid Tumors
Interventions
IBI3014Drug
12 mg/kg D1 IV Q3W
IBI3014Drug
6 mg/kg D1 IV Q3W
IBI3014Drug
1 mg/kg D1 IV Q3W
IBI3014Drug
15 mg/kg D1 IV Q3W
IBI3014Drug
9 mg/kg D1 IV Q3W
IBI3014Drug
3 mg/kg D1 IV Q3W
IBI3014Drug
20 mg/kg D1 IV Q3W
IBI3014Drug
18 mg/kg D1 IV Q3W
Primary outcomes
What the sponsor says the trial is designed to measure.
- The Safety profile of patients in Phase 1 dose escalation part、Phase 1 dose expansion and Phase 2 dose optimizationTime frame: 2 years after LPI
- Dose limiting toxicity (DLT) of IBI3014 in Phase 1 dose escalationTime frame: 21 days after LPI
- ORR per RECIST v1.1 in Phase 1 dose expansion and Phase 2 dose optimizationTime frame: 2 years after LPI
- The Safety profile of patients in Phase 1 dose escalation part、Phase 1 dose expansion and Phase 2 dose optimizationTime frame: 2 years after LPI
- The Safety profile of patients in Phase 1 dose escalation part、Phase 1 dose expansion and Phase 2 dose optimizationTime frame: 2 years after LPI
- The Safety profile of patients in Phase 1 dose escalation part、Phase 1 dose expansion and Phase 2 dose optimizationTime frame: 2 years after LPI
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Fujian cancer hospital
Fuzhou, Fujian, China · Recruiting
Hunan Cancer Hospital
Changsha, Hunan, China · Recruiting
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.